Eli Lilly Launches Innovative Drug 'Mounjaro' to Combat Obesity and Diabetes in India

Eli Lilly and Company (India) has launched 'Mounjaro,' a novel medication for obesity and type 2 diabetes, after receiving approval from the CDSCO. Mounjaro, an adjunct to diet and exercise, activates GIP and GLP-1 receptors and is aimed at improving weight management and glycemic control in adults.

Eli Lilly and Company (India) announced a significant breakthrough on Thursday with the launch of 'Mounjaro,' a first-of-its-kind medication designed to treat obesity and type 2 diabetes. The development follows approval from the Central Drugs Standard Control Organisation (CDSCO).

This innovative drug combines the activation of GIP and GLP-1 hormone receptors, tailored for chronic weight management and improving glycemic control in adults. 'Mounjaro' aims at providing a new solution for adults with a BMI of 30 kg/m2 or greater, or 27 kg/m2 with comorbid conditions.

India faces a dual health challenge with obesity and diabetes affecting millions. 'Mounjaro' provides a once-a-week treatment that could be a game-changer in managing these conditions. Eli Lilly India's President, Winselow Tucker, emphasized their commitment to tackling this public health issue in collaboration with the government and industry.